small steps great leaps

Chronic pain and the associated problems drug-based therapies bring to this condition are one of the biggest healthcare issues facing the world today.
Exsurgo is here to change that.

Exsurgo combines neuroscience, engineering and data analysis to help treat a range of neurological conditions without the use of, and more effectively than, pharmaceuticals.

From chronic pain – one of the biggest healthcare issues facing the world today – to concussion, from stroke rehabilitation to post-traumatic stress disorder, from anxiety and depression to endometriosis, Exsurgo’s technology – and its centralised data collection hub Exsurgo Connect – analyses brain activity and then puts the power of our own brains to use to help treat those conditions.

Using artificial intelligence, Exsurgo will also be able to diagnose a range of neurological conditions and offer personalised treatments.

Mindpower to the people

A REVOLUTION IN PAIN MANAGEMENT, EXSURGO’S PROPRIETARY AXON SYSTEM IS  NON-INVASIVE, EASY-TO-USE AND HAS NO SIDE- EFFECTS OR TOLERANCE BUILD UP.

When wearing the headset, brain-activity data is tracked and displayed on the user’s own mobile device via our app. Through real-time visual feedback, the user learns to neuro- modulate the pain signals by recognising and modifying their response, causing a significant decrease in pain. At a fraction of the price of traditional EEG technology, Axon empowers everyone, everywhere to manage their own treatment from the comfort of their own home.

HOW AXON WORKS

Electroencephalography (EEG) Neurofeedback is an established, medically-proven process used to evaluate electrical activity in the brain. Based on the proven science that people learn by positive (and negative) reinforcement, patients can ‘retrain’ their brains to respond to pain signals in a different way. 

Most major hospitals and medical universities will have an EEG machine, but using one currently requires attendance at a specialist clinic and a clinician is needed to interpret data. The equipment can also cost up to hundreds of thousands of dollars. 

Axon technology combines a miniaturised headset, Cloud-based AI for analytics, and a consumer-friendly app. Exsurgo intends to market Axon as a medical-grade service at a fraction of the cost of existing systems, making EEG Neurofeedback affordable and accessible for the first time. 

The therapy is non-invasive and drug- and side-effect free and it can be done at a clinic or at home with clinical oversight – allowing patients to deal with their chronic pain via an Axon subscription, rather than via drug prescription. 

Neurofeedback also has exciting potential for treating a wide range of health conditions that have a neurological component, including anxiety & depression, migraine, PTSD and ADHD. Exsurgo has an extensive programme of clinical trials and studies underway to validate the use of its technology.

 

The deployment of Exsurgo’s technology has the potential to save the UK healthcare economy in the region of US$7.9B per year.

EXTRACT FROM TREATING CHRONIC SEVERE PAIN: THE ROLE OF AXON IN REDUCING GLOBAL COSTS.

Dr Nick Birch FRCS (Orth), Consultant Spinal Specialist

CLINICAL TRIALS

Early clinical studies in the treatment of chronic pain have shown that in-home use of EEG combined with Neurofeedback can be more effective than the current best practice pharmaceuticals.

A UK clinical trial saw 20 trial participants who suffered from various types of chronic pain using Axon from the comfort of their own home to measure changes in pain intensity alongside associated symptoms (depression, anxiety, sleep, and quality of life). The trial was led by Dr Nick Birch, an Orthopaedic Consultant, and his analysis suggests the deployment of Axon has the potential to save the UK healthcare economy in the region of £5.8 billion per year. 

In the US, he says the potential impact of Axon is three times as great as in the UK in terms of cost-effectiveness, but will also have a major impact on reducing opiate dependence and the annual death toll from opiate overdoses. 

Another, larger clinical trial will start soon in Auckland, New Zealand and it is being run in conjunction with AUT University and the Waitemata District Health Board.

CLINICAL STUDIES By EXSURGO ARE ONGOING AND PROGRESSING WELL WITH RESULTS EXPECTED IN Q2 2021.